Myoinositol and D-chiroinositol in the treatment of patients with anovulatory infertility associated with metabolic disorders: debatable issues

1. Hazlina N.N.H., Norhayati M.N., Bahari S.I., Arif N.M. Worldwide prevalence, risk factors and psychological impact of infertility among women: a systematic review and meta-analysis. BMJ Open. 2022; 12(3): e057132. https://dx.doi.org/10.1136/bmjopen-2021-057132
2. Савина А.А., Землянова Е.В., Фейгинова С.И. Потери потенциальных рождений в г. Москве за счет женского и мужского бесплодия. Здоровье мегаполиса. 2022; 3(3): 39-45. [Savina A.A., Zemlyanova E.V., Feiginova S.I. Potential births loss due to male and female infertility in Moscow. City Healthcare. 2022; 3(3): 39-45 (in Russian)]. https://dx.doi.org/10.47619/2713-2617.zm.2022.v.3i3;39-45
3. Абсатарова Ю.С., Евсеева Ю.С., Андреева Е.Н. Нейроэндокринные особенности патогенеза синдрома поликистозных яичников (обзор литературы). Проблемы эндокринологии. 2023; 69(5): 107-14. [Absatarova Yu.S., Evseeva Yu.S., Andreeva E.N. Neuroendocrine features of the pathogenesis of polycystic ovary syndrome (literature review). Problems of Endocrinology. 2023; 69(5): 107-14 (in Russian)]. https://dx.doi.org/10.14341/probl13350
4. Turner F., Powell S.G., Al-Lamee H., Gadhvi A., Palmer E., Drakeley A. et al. Impact of BMI on fertility in an otherwise healthy population: a systematic review and meta-analysis. BMJ Open 2024; 14(10): e082123. https://dx.doi.org/10.1136/bmjopen-2023-082123
5. Collée J., Mawet M., Tebache L., Nisolle M., Brichant G. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecol. Endocrinol. 2021; 37(10): 869-74. https://dx.doi.org/10.1080/09513590.2021.1958310
6. Алфёрова В.И., Мустафина С.В. Распространенность ожирения во взрослой популяции Российской Федерации (обзор литературы). Ожирение и метаболизм. 2022; 19(1): 96-105. [Alferova V.I., Mustafina S.V. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and metabolism. 2022; 19(1): 96-105 (in Russian)]. https://dx.doi.org/10.14341/omet12809
7. Muscogiuri G., Verde L., Vetrani C., Barrea L., Savastano S., Colao A. Obesity: a gender-view. J. Endocrinol. Invest. 2024; 47(2): 299-306 https://dx.doi.org/10.1007/s40618-023-02196-z
8. Chung H.F., Ferreira I., Mishra G.D. The association between menstrual symptoms and hypertension among young women: a prospective longitudinal study. Maturitas. 2021; 143: 17-24. https://dx.doi.org/10.1016/j.maturitas.2020.08.006
9. Liao C.C., Lee C.I., Liao K.R., Li J.M. Association between serum glycated hemoglobin levels and female infertility: a cross-sectional survey and genetic approach. Int. J. Mol. Sci. 2024; 25(17): 9668. https://dx.doi.org/10.3390/ijms25179668
10. Arias A., Quiroz A., Santander N., Morselli E., Busso D. Implications of high-density cholesterol metabolism for oocyte biology and female fertility. Front. Cell Dev. Biol. 2022 Sep 14; 10: 941539. https://dx.doi.org/10.3389/fcell.2022.941539
11. Zhu X., Hong X., Wu J., Zhao F., Wang W., Huang L. et al. The Association between circulating lipids and female infertility risk: a univariable and multivariable mendelian randomization analysis. Nutrients. 2023; 15(14): 3130. https://dx.doi.org/10.3390/nu15143130
12. Lu F.F., Wang Z., Yang Q.Q., Yan F.S., Xu C., Wang M.T. et al. Investigating the metabolomic pathways in female reproductive endocrine disorders: a mendelian randomization study. Front. Endocrinol. (Lausanne). 2024; 15: 1438079. https://dx.doi.org/10.3389/fendo.2024.1438079
13. Cochran L., Nadolny R., Garcia K., Kluglein K.A., Yagoda A. et al. Available treatments and adjunctive therapies for polycystic ovarian syndrome (PCOS) patients of reproductive age: a scoping review. Cureus. 2024; 16(9): e70501. https://dx.doi.org/10.7759/cureus.70501
14. Garg D., Tal R. Inositol treatment and ART outcomes in women with PCOS. Int. J. Endocrinol. 2016; 2016: 1979654. https://dx.doi.org/10.1155/2016/1979654
15. Громова О.А., Торшин И.Ю., Гришина Т.Р., Громов А.., Лиманова О.А. Систематический анализ молекулярно-физиологических эффектов миоинозитола: данные молекулярной биологии, экспериментальной и клинической медицины. Эффективная фармакотерапия. 2013; 28: 4-12. [Gromova O.A., Torshin I.Yu., Grishina T.R., Gromov A., Limanova O.A. Systematic analysis of molecular-physiological effects of myo-inositol: data of molecular biology, experimental and clinical medicine. Effective Pharmacotherapy. 2013; 28: 4-12 (in Russian)].
16. Wojciechowska A., Osowski A., Jóźwik M., Górecki R., Rynkiewicz A., Wojtkiewicz J. Inositols' importance in the improvement of the endocrine-metabolic profile in PCOS. Int. J. Mol. Sci. 2019; 20(22): 5787. https://dx.doi.org/10.3390/ijms20225787
17. Pandey C., Maunder A., Liu J., Vaddiparthi V., Costello M.F., Bahri-Khomami M. et al. The role of nutrient supplements in female infertility: an umbrella review and hierarchical evidence synthesis. Nutrients. 2025; 17(1): 57. https://dx.doi.org/10.3390/nu17010057
18. Turek K., Greguła A., Stachyrak K., Mika D., Kłos A., Mazur B. et al. The role of inositol in improving fertility in patients with PCOS. J. Educ. Health Sport. 2024; 57: 126-39. https://dx.doi.org/10.12775/JEHS.2024.57.009
19. Unfer V. D-chiro-inositol in PCOS: the myths and what we know about the reality. Int. J. Food Scien. Nutr. 2022; 73(7): 989-91. https://dx.doi.org/10.1080/09637486.2022.2089638
20. Carlomagno G., Unfer V., Roseff S. The D-chiro-inositol paradox in the ovary. Fertil. Steril. 2011; 95(8): 2515-6. https://dx.doi.org/10.1016/j.fertnstert.2011.05.027
21. Isabella R., Raffone E. CONCERN: does ovary need D-chiro-inositol? J. Ovarian Res. 2012; 5(1): 14. https://dx.doi.org/10.1186/1757-2215-5-14
22. Isabella R., Raffone E. Expression of concern to: does ovary need D-chiro-inositol? J. Ovarian Res. 2018; 11(1): 57. https://dx.doi.org/10.1186/s13048-018-0431-y
23. Unfer V., Dinicola S., Russo M. A PCOS paradox: does inositol therapy find a rationale in all the different phenotypes? Int. J. Mol. Sci. 2023; 24(7): 6213. https://dx.doi.org/10.3390/ijms24076213
24. Zhao H., Zhang J., Cheng X., Nie X., He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J. Ovarian Res. 2023; 16: 9. https://dx.doi.org/10.1186/s13048-022-01091-0
25. Bizzarri M., Monti N., Piombarolo A., Angeloni A., Verna R. Myo-inositol and D-chiro-inositol as modulators of ovary steroidogenesis: a narrative review. Nutrients. 2023; 15(8): 1875. https://dx.doi.org/10.3390/nu15081875
26. Placidi M., Casoli G., Tatone C., Di Emidio G., Bevilacqua A. Myo-inositol and its derivatives: their roles in the challenges of infertility. Biology (Basel). 2024; 13(11): 936. https://dx.doi.org/10.3390/biology13110936
27. Facchinetti F., Orrù B., Grandi G., Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol. Endocrinol. 2019; 35(3): 198-206. https://dx.doi.org/10.1080/09513590.2018.1540578
28. Azizi Kutenaei M., Hosseni Teshnizi S., Ghaemmaghami P., Eini F., Roozbeh N. The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. Eur. Rev. Med. Pharmacol. Sci. 2021; 25(7): 3105-15. https://dx.doi.org/10.26355/eurrev_202104_25565
29. DiNicolantonio J.J., O'Keefe J.H. Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. 2022; 9(1): e001989. https://dx.doi.org/10.1136/openhrt-2022-001989
30. Laganà A.S., Barbaro L., Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-chiro-inositol. Arch. Gynecol. Obstet. 2015; 291(5): 1181-6. https://dx.doi.org/10.1007/s00404-014-3552-6
31. Gambioli R., Forte G., Aragona C., Bevilacqua A., Bizzarri M., Unfer V. The use of D-chiro-inositol in clinical practice. Eur. Rev. Med. Pharmacol. Sci. 2021; 25(1): 438-46. https://dx.doi.org/10.26355/eurrev_202101_24412
32. Pizzo A., Laganà A.S., Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol. Endocrinol. 2014; 30(3): 205-8. https://dx.doi.org/10.3109/09513590.2013.860120
33. Gupta D., Khan S., Islam M., Malik B.H., Rutkofsky I.H. Myo-inositol's role in assisted reproductive technology: evidence for improving the quality of oocytes and embryos in patients with polycystic ovary syndrome. Cureus. 2020; 12(5): e8079. https://dx.doi.org/10.7759/cureus.8079
34. Facchinetti F., Espinola M.S.B., Dewailly D., Ozay A.C., Prapas N., Vazquez-Levin M. et al.; Expert Group on Inositols in Preclinical and Clinical Research. Breakthroughs in the use of inositols for assisted reproductive treatment (ART). Trends Endocrinol. Metab. 2020; 31(8): 570-9. https://dx.doi.org/10.1016/j.tem.2020.04.003
35. Mendoza N., Pérez L., Simoncini T., Genazzani A. Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod. Biomed. Online. 2017; 35(5): 529-35. https://dx.doi.org/10.1016/j.rbmo.2017.07.005
36. Greff D., Juhász A.E., Váncsa S., Váradi A., Sipos Z., Szinte J. et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod. Biol. Endocrinol. 2023; 21(1): 10. https://dx.doi.org/10.1186/s12958-023-01055-z
37. Fatima K., Jamil Z., Faheem S., Adnan A., Javaid S.S., Naeem H. et al. Effects of myo-inositol vs metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis. Ir. J. Med. Sci. 2023; 192(6): 2801-8. https://dx.doi.org/10.1007/s11845-023-03388-5
38. Zhang J.Q., Xing C., He B. Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. Eur. Rev. Med. Pharmacol. Sci. 2022; 26(6): 1792-802. https://dx.doi.org/10.26355/eurrev_202203_2832
39. Bodepudi R., Seher S., Khan S.A., Emmanuel S., Kumar V.S., Nerella R. et al. Myoinositol versus metformin in the treatment of polycystic ovarian syndrome: a systematic review. Cureus. 2023; 15(7): e41748. https://dx.doi.org/10.7759/cureus.41748
40. Zhao H., Xing C., Zhang J., He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod. Health. 2021; 18(1): 171. https://dx.doi.org/10.1186/s12978-021-01207-7
41. Lin L., Chen G., Qiao X., Chen Y., Deng H., Xu L. Comparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome in women with polycystic ovary syndrome: a systematic review and network meta-analysis. J. Ovarian. Res. 2024; 17(1): 249. https://dx.doi.org/10.1186/s13048-024-01576-0
42. Fitz V., Graca S., Mahalingaiah S., Liu J., Lai L., Butt A. et al. Inositol for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 update of the international evidence-based PCOS guidelines. J. Clin. Endocrinol. Metab. 2024; 109(6): 1630-55. https://dx.doi.org/10.1210/clinem/dgad762
43. Unanyan A., Pivazyan L., Krylova E., Eskin A., Zakaryan A., Sarkisova A., Ishchenko A. Effectiveness of inositol, metformin and their combination in women with PCOS undergoing assisted reproduction: systematic review and meta-analysis. Gynecol. Endocrinol. 2022; 38(12): 1035-46. https://dx.doi.org/10.1080/09513590.2022.2136160
44. Nazirudeen R., Sridhar S., Priyanka R., Sumathi B., Natarajan V., Subbiah E. et al. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. Clin. Endocrinol. (Oxf.). 2023; 99(2): 198-205. https://dx.doi.org/10.1111/cen.14931
45. Bahadur A., Arora H., Ravi A.K., Naithani M., Bahurupi Y., Chaturvedi J. et al. Comparison of clinical, metabolic and hormonal effects of metformin versus combined therapy of metformin with myoinositol plus D-chiro-inositol in women with polycystic ovary syndrome (PCOS): a randomized controlled trial. Cureus. 2021; 13(6): e15510. https://dx.doi.org/10.7759/cureus.15510
46. Kelly F.A., de Oliveira Macena Lôbo A., Cardoso J.H.C.O., de Moraes F.C.A. Comparison of metformin with inositol versus metformin alone in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2025; 87(2): 389-99. https://dx.doi.org/10.1007/s12020-024-04052-3
47. Jethaliya H., Gajjar N., Patel V., Deshpande S., Patel R. Efficacy of myo-inositol on anthropometric, metabolic, and endocrine outcomes in PCOS patients: a meta-analysis of randomized controlled trial. Reprod. Sci. 2022; 29(8): 2282-98. https://dx.doi.org/10.1007/s43032-022-00933-y
48. Chan S.Y., Barton S.J., Loy S.L., Chang H.F., Titcombe P., Wong J.T. et al. Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics, and micronutrient supplement: secondary outcomes of the NiPPeR randomized trial. Fertil. Steril. 2023; 119(6): 1031-42. https://dx.doi.org/10.1016/j.fertnstert.2023.01.047
49. Kamenov Z., Gateva A., Dinicola S., Unfer V. Comparing the efficacy of myo-inositol plus α-Lactalbumin vs myo-inositol alone on reproductive and metabolic disturbances of polycystic ovary syndrome. Metabolites. 2023; 13(6): 717. https://dx.doi.org/10.3390/metabo13060717
50. Zarezadeh M., Dehghani A., Faghfouri A.H., Radkhah N., Kermanshahi M.N., Kalajahi F.H. et al. Inositol supplementation and body mass index: a systematic review and meta-analysis of randomized clinical trials. Obes. Sci. Pract. 2021 22; 8(3): 387-97. https://dx.doi.org/10.1002/osp4.569
51. Formoso G., Baldassarre M.P.A., Ginestra F., Carlucci M.A., Bucci I., Consoli A. Inositol and antioxidant supplementation: safety and efficacy in pregnancy. Diabetes Metab. Res. Rev. 2019; 35(5): e3154. https://dx.doi.org/10.1002/dmrr.3154
52. Kalra B., Kalra S., Sharma J.B. The inositols and polycystic ovary syndrome. Indian. J. Endocrinol. Metab. 2016; 20(5): 720-4. https://dx.doi.org/10.4103/2230-8210.189231
53. Dinicola S., Unfer V., Facchinetti F., Soulage C.O., Greene N.D., Bizzarri M. et al. Inositols: from established knowledge to novel approaches. Int. J. Mol. Sci. 2021; 22(19): 10575. https://dx.doi.org/10.3390/ijms221910575
54. Facchinetti F., Unfer V., Dewailly D., Kamenov Z.A., Diamanti-Kandarakis E., Laganà A.S. et al. Inositols in polycystic ovary syndrome: an overview on the advances. Trends Endocrinol. Metab. 2020; 31(6): 435-47. https://dx.doi.org/10.1016/j.tem.2020.02.002
55. Ranaldi G., Ferruzza S., Natella F., Unfer V., Sambuy Y., Monastra G. Enhancement of D-chiro-inositol transport across intestinal cells by alpha-lactalbumin peptides. Eur. Rev. Med. Pharmacol. Sci. 2020; 24(19): 10143-54. https://dx.doi.org/10.26355/eurrev_202010_23234
56. Громова О.А., Торшин И.Ю., Уварова Е.B., Тапильская Н.И., Калачева А.Г. Систематический анализ биологических ролей и фармакологических свойств D-хиро-инозитола. Гинекология. 2020; 22(3): 21-8 [Gromova O.A., Torshin I.Yu., Uvarova E.V., Tapilskaya N.I., Kalacheva A.G. Systematic analysis of the biological roles and pharmacological properties of D-chiro-inositol. Gynecology. 2020; 22(3): 21-8 (in Russian)]. https://dx.doi.org/10.26442/20795696.2020.3.200210
57. Kiani A.K., Paolacci S., Calogero A.E., Cannarella R. et al. From myo-inositol to D-chiro-inositol molecular pathways. Eur. Rev. Med. Pharmacol. Sci. 2021; 25(5): 2390-2402. https://dx.doi.org/10.26355/eurrev_202103_25279
58. Pustotina O., Myers S.H., Unfer V., Rasulova I. The effects of myo-inositol and D-chiro-inositol in a ratio 40:1 on hormonal and metabolic profile in women with polycystic ovary syndrome classified as phenotype a by the Rotterdam criteria and EMS-type 1 by the EGOI criteria. Gynecol. Obstet. Invest. 2024; 89(2): 131-9. https://dx.doi.org/10.1159/000536163
59. Januszewski M., Issat T., Jakimiuk A.A., Santor-Zaczynska M., Jakimiuk A.J. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol. Pol. 2019; 90(1): 7-10. https://dx.doi.org/10.5603/GP.2019.0002
60. Аляутдина О.С., Прилуцкая В.Ю. Сравнение эффективности применения инозитолов и комбинированных оральных контрацептивов для коррекции метаболических, эндокринных и клинических параметров пациенток с синдромом поликистозных яичников. Вопросы гинекологии, акушерства и перинатологии. 2022; 21(1): 43-50. [Alyautdina O.S., Prilutskaya V.Yu. Comparison of efficacy of inositol and combined oral contraceptives for correction of metabolic, endocrine, and clinical parameters in patients with polycystic ovary syndrome. Gynecology, Obstetrics and Perinatology. 2022; 21(1): 43-50 (in Russian)]. https://dx.doi.org/10.20953/1726-1678-2022-1-43-50
61. Доброхотова Ю.Э., Лапина И.А., Чирвон Т.Г., Таранов В.В. Новые возможности интегративной терапии пациенток с синдромом поликистозных яичников и нарушениями углеводного и липидного обмена. Результаты сравнительного исследования. РМЖ. Мать и дитя. 2020; 3(3): 169-73 [Dobrokhotova Yu.E., Lapina I.A., Chirvon T.G., Taranov V.V. New possibilities of integrative therapy of patients with polycystic ovary syndrome and carbohydrate and lipid metabolism disorders. Results of a comparative study. RMJ. Mother and child. 2020; 3(3): 169-73 (in Russian)]. https://dx.doi.org/10.32364/2618-8430-2020-3-3-169-173
62. Прилуцкая В.Ю., Аляутдина О.С., Сосна Н.А. Влияние комбинации миоинозитола и D-хироинозитола в соотношении 5:1 на психоэмоциональное состояние и проявления андрогензависимой дермопатии у пациенток с синдромом поликистозных яичников. Проблемы репродукции. 2021; 27(4): 97-107. [Prilutskaya V.Yu., Alyautdina O.S., Sosna N.A. The effect of the combination of myoinositol and D-chiroinositol in a ratio of 5:1 on the psychoemotional state and manifestations of androgen-dependent dermopathy in patients with polycystic ovary syndrome. Russian Journal of Human Reproduction. 2021; 27(4): 97-107 (in Russian)]. https://dx.doi.org/10.17116/repro20212704197
63. Обоскалова Т.А., Воронцова А.В., Звычайный М.А., Гущина К.Г., Майтесян М.М. Результаты применения комбинации миоинозитола и D-хироинозитола в соотношении 5:1. Гинекология. 2020; 22(6): 104-9. [Oboskalova T.A., Vorontsova A.V., Zvycheyny M.A., Gushchina K.G., Maitesyan M.M. Results of using a combination of myoinositol and D-chiroinositol in a ratio of 5:1. Gynecology. 2020; 22(6): 104-9 (in Russian)]. https://dx.doi.org/10.26442/20795696.2020.6.200548
64. Тапильская Н.И., Сажина И.Н., Андреева М.Д., Сорокина О.В. Эффективность применения комбинации миоинозитола и D-хироинозитола в соотношении 5:1 с марганцем и фолиевой кислотой у пациенток репродуктивного возраста с нерегулярным менструальным циклом и ожирением. Гинекология. 2022; 24(2): 101-7. [Tapilskaya N.I., Sazhina I.N., Andreeva M.D., Sorokina O.V. Efficiency of using a combination of myoinositol and D-chiroinositol in a 5:1 ratio with manganese and folic acid in patients of reproductive age with irregular menstrual cycle and obesity. Gynecology. 2022; 24(2): 101-7 (in Russian)]. https://dx.doi.org/10.26442/20795696.2022.2.201393
65. Эфендиева Р.М., Дикке Г.Б., Абусуева З.А., Шилова Н.В. Опыт восстановления менструального цикла у пациенток с олиго-/аменореей и ожирением с помощью комплекса, содержащего миоинозитол и D-хироинозитол в соотношении 5:1, фолиевую кислоту и марганец. Акушерство и гинекология. 2025; 2: 110-20. [Efendieva R.M., Dikke G.B., Abusueva Z.A., Shilova N.V. Experience of restoring the menstrual cycle in patients with oligo-/amenorrhea and obesity using a complex containing myoinositol and D-chiroinositol in a ratio of 5:1, folic acid and manganese. Obstetrics and Gynecology. 2025; (2): 110-20 (in Russian)]. https://dx.doi.org/10.18565/aig.2025.31
66. Mendoza N., Galan M.I., Molina C., Mendoza-Tesarik R., Conde C., Mazheika M. et al. High dose of D-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol. Endocrinol. 2020; 36: 398-401. https://dx.doi.org/10.1080/09513590.2019.1681959
67. Mendoza N., Diaz-Ropero M.P., Aragon M., Maldonado V., Llaneza P., Lorente J. et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol. Endocrinol. 2019; 35(8): 695-700. https://dx.doi.org/10.1080/09513590.2019.1576620
68. Kachhawa G., Kumar K.V.S., Kulshrestha V., Khadgawat R., Mahey R., Bhatla N. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study. Int. J. Gynaecol. Obstet. 2022; 158(2): 278-84. https://dx.doi.org/10.1002/ijgo.13971
69. Vyas L., Raiturker A.P., Sud S., Goyyal P., Abhyankar M., Revankar S. et al. Management of polycystic ovary syndrome among Indian women using myo-inositol and D-chiro-inositol. Bioinformation. 2022; 18(2): 103-10. https://dx.doi.org/10.6026/97320630018103
70. Sortino M.A., Salomone S., Carruba M.O., Drago F. Polycystic ovary syndrome: insights into the therapeutic approach with inositols. Front. Pharmacol. 2017; 8: 341. https://dx.doi.org/10.3389/fphar.2017.00341
71. Nordio M., Basciani S., Camajani E. The 40:1 myo-inositol / D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur. Rev. Med. Pharmacol. Sci. 2019; 23(12): 5512-21. https://dx.doi.org/10.26355/eurrev_201906_18223
72. Armijo-Sánchez A., Castillo N.B., García-Vidal E., Luna Chadid M., Salvador Ballada C.S. et al. Treatment with a patented 3.6:1 myo-inositol to D-chiro-inositol ratio, antioxidants, vitamins and minerals food supplement in women with a history of assisted reproductive technique (ART) failures: a series of case reports. Clin. Med. Insights Case Rep. 2024; 17: 11795476241242265. https://dx.doi.org/10.1177/11795476241242265
73. Carlomagno G., Grazia S. de, Unfer V., Manna F. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin. Drug Deliv. 2012; 9(3): 267-71. https://dx.doi.org/10.1517/17425247.2012.662953
74. López-Gambero A.J., Sanjuan C., Serrano-Castro P.J., Suárez J., Rodríguez de Fonseca F. The biomedical uses of inositols: a nutraceutical approach to metabolic dysfunction in aging and neurodegenerative diseases. Biomedicines. 2020; 8(9): 295. https://dx.doi.org/10.3390/biomedicines8090295
75. Orrù B., Circo R., Logoteta P., Petousis S., Carlomagno G. Finding the best therapeutic approach for PCOS: the importance of inositol(s) bioavailability. Eur. Rev. Med. Pharmacol. Sci. 2017; 21(2 Suppl.): 83-8. https://pubmed.ncbi.nlm.nih.gov/28724181/
76. Министерство здравоохранения Российской Федерации. Синдром поликистозных яичников. Клинические рекомендации. М.; 2024. 66 с. [Ministry of Health of the Russian Federation. Polycystic ovary syndrome. Clinical guidelines. Moscow; 2024. 66 p. (in Russian)].
77. Teede H., Tay C.T., Laven J., Dokras A., Moran L., Piltonen T. et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS). Melbourne: Monash University; 2023. 258 р. https://dx.doi.org/10.26180/24003834.v1

Received 26.06.2025

Accepted 07.07.2025